Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model

• 主要な著者: Daniel Valente Neves (著者), Carolina Pinto Vieira (著者), Adriana Rocha (著者), Vera Lucia Lanchote (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2018-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

PURPOSE: Ceftriaxone elimination occurs through breast cancer resistance transporter (BCRP) and multidrug resistance-associated protein 2 (MRP-2) which are expressed on the canalicular membrane of hepatocytes. Eltrombopag, a thrombopoetin receptor agonist used in the treatment of immune thrombocytop...